Advate

Advate is a recombinant antihemophilic factor (rAHF) used in the treatment of hemophilia A. It is a medication designed to replace the missing or deficient factor VIII in patients with hemophilia A, a genetic disorder that impairs the body's ability to make blood clots, a process needed to stop bleeding.

Composition and Production

Advate is produced using recombinant DNA technology. It is a purified glycoprotein consisting of 2332 amino acids, with a molecular weight of approximately 280 kDa. The production process involves the use of Chinese hamster ovary cells (CHO cells) to express the factor VIII protein, which is then purified and formulated for therapeutic use.

Indications

Advate is indicated for:

• Control and prevention of bleeding episodes in patients with hemophilia A.
• Perioperative management (surgical prophylaxis) in patients with hemophilia A.
• Routine prophylaxis to reduce the frequency of bleeding episodes and the risk of joint damage in patients with hemophilia A.

Administration

Advate is administered via intravenous injection. The dosage and frequency of administration depend on the severity of the factor VIII deficiency, the location and extent of bleeding, and the patient's clinical condition.

Side Effects

Common side effects of Advate include:

• Headache
• Fever
• Nausea
• Vomiting
• Injection site reactions

Serious side effects may include the development of inhibitors (antibodies) to factor VIII, which can reduce the effectiveness of the treatment.

Storage and Handling

Advate should be stored in a refrigerator at a temperature of 2°C to 8°C (36°F to 46°F). It should not be frozen. Before administration, the product can be kept at room temperature (up to 25°C or 77°F) for a limited period, as specified by the manufacturer.

Related Pages

• Hemophilia A
• Factor VIII
• Recombinant DNA technology
• Chinese hamster ovary cells
• Intravenous injection

See Also

• Hemophilia B
• Blood clotting
• Genetic disorders

External Links

-